What is it about?
We developed a quantitative pharmacophore for NTCP inhibitors. We also tried to look at which compounds were associated with drug induced liver injury -DILI. We collated 94 compounds and found them equally distributed suggesting no relationship between NTCP inhibition and DILI risk.
Featured Image
Why is it important?
Inhibiting NTCP may prevent Hepatitis B uptake. We also list the biggest dataset of inhibitors tested to this point in time. Curating the DILI data is also potentially useful in the light of interest in understanding this toxicity. Seperating DILI from NTCP inhibition suggests that treatments for Hepatitis B via inhibition of NTCP may be feasible.
Perspectives
A project with clinical implications. The model could be used to prioritize additional compounds (FDA drugs and novel compounds) for testing. Validation of this model suggests it may have utility.
Dr Sean Ekins
Collaborations in Chemistry
Read the Original
This page is a summary of: Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition, European Journal of Pharmaceutical Sciences, January 2015, Elsevier,
DOI: 10.1016/j.ejps.2014.09.005.
You can read the full text:
Contributors
The following have contributed to this page
